| scholarly article | Q13442814 |
| P50 | author | Hugo A. Katus | Q27929168 |
| Michael J Pencina | Q37382178 | ||
| P2093 | author name string | Kai C Wollert | |
| Tibor Kempf | |||
| Evangelos Giannitsis | |||
| Allison Meisner | |||
| Christian Widera | |||
| Kerstin Bethmann | |||
| Ivonne Marquardt | |||
| P2860 | cites work | GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. | Q54623768 |
| Growth Differentiation Factor 15 for Risk Stratification and Selection of an Invasive Treatment Strategy in Non ST-Elevation Acute Coronary Syndrome | Q56593478 | ||
| GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice | Q58807888 | ||
| Risk scores for risk stratification in acute coronary syndromes: useful but simpler is not necessarily better | Q80166728 | ||
| Management patterns in relation to risk stratification among patients with non-ST elevation acute coronary syndromes | Q80392835 | ||
| Use of cardiac catheterization for non-ST-segment elevation acute coronary syndromes according to initial risk: reasons why physicians choose not to refer their patients | Q80681992 | ||
| Growth-differentiation factor-15 for long-term risk prediction in patients stabilized after an episode of non-ST-segment-elevation acute coronary syndrome | Q82921408 | ||
| Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial | Q83022241 | ||
| Clinical scores and patient risk stratification in non-ST elevation acute coronary syndrome | Q84150081 | ||
| C-reactive protein improves risk prediction in patients with acute coronary syndromes | Q84173219 | ||
| ??? | Q22242895 | ||
| Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE) | Q22242088 | ||
| Universal definition of myocardial infarction: Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction | Q22242900 | ||
| MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily | Q24317134 | ||
| Does simplicity compromise accuracy in ACS risk prediction? A retrospective analysis of the TIMI and GRACE risk scores | Q30947051 | ||
| The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury | Q33231048 | ||
| Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data | Q33548587 | ||
| Guidelines on myocardial revascularization | Q34134730 | ||
| Intervention in acute coronary syndromes: do patients undergo intervention on the basis of their risk characteristics? The Global Registry of Acute Coronary Events (GRACE) | Q35773204 | ||
| Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers | Q35927436 | ||
| Cardiovascular risk prediction in patients with stable and unstable coronary heart disease | Q37766725 | ||
| 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): a report of the American College of Cardiology Foundation/American Heart Associ | Q37858859 | ||
| Growth-differentiation factor-15 for risk stratification in patients with stable and unstable coronary heart disease: results from the AtheroGene study | Q39916498 | ||
| Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study | Q39967372 | ||
| Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay | Q40257914 | ||
| Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials | Q40414100 | ||
| N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arte | Q40576611 | ||
| Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome | Q43715189 | ||
| Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis | Q44086539 | ||
| Understanding physicians' risk stratification of acute coronary syndromes: insights from the Canadian ACS 2 Registry | Q44412543 | ||
| Involvement of growth differentiation factor-15/macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in oxLDL-induced apoptosis of human macrophages in vitro and in arteriosclerotic lesions | Q45086910 | ||
| TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS. | Q46375283 | ||
| Relative value of N-terminal probrain natriuretic peptide, TIMI risk score, ACC/AHA prognostic classification and other risk markers in patients with non-ST-elevation acute coronary syndromes | Q47612416 | ||
| Improving long-term risk prediction in patients with acute chest pain: the Global Registry of Acute Coronary Events (GRACE) risk score is enhanced by selected nonnecrosis biomarkers | Q48143560 | ||
| Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. | Q48329269 | ||
| The report card on growth differentiation factor 15: consistent marks but not yet ready for promotion | Q48370183 | ||
| A comparison between B-type natriuretic peptide, global registry of acute coronary events (GRACE) score and their combination in ACS risk stratification | Q48689752 | ||
| The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes | Q48766104 | ||
| Results from a multicenter evaluation of the 4th generation Elecsys Troponin T assay. | Q51921592 | ||
| P433 | issue | 9 | |
| P304 | page(s) | 1095-1104 | |
| P577 | publication date | 2011-12-23 | |
| P1433 | published in | European Heart Journal | Q2286839 |
| P1476 | title | Adjustment of the GRACE score by growth differentiation factor 15 enables a more accurate appreciation of risk in non-ST-elevation acute coronary syndrome | |
| P478 | volume | 33 |
| Q35971451 | Adjustment of the GRACE score by HemoglobinA1c enables a more accurate prediction of long-term major adverse cardiac events in acute coronary syndrome without diabetes undergoing percutaneous coronary intervention |
| Q38172885 | Biomarkers and acute coronary syndromes: an update |
| Q57059379 | Blood homocysteine levels could predict major adverse cardiac events in patients with acute coronary syndrome: A STROBE-compliant observational study |
| Q38232835 | Cardiac biomarkers for infarct diagnosis and early exclusion of acute coronary syndrome |
| Q35808028 | Combined Value of Red Blood Cell Distribution Width and Global Registry of Acute Coronary Events Risk Score for Predicting Cardiovascular Events in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention |
| Q64055340 | Comparison short time discharge with long time discharge following uncomplicated percutaneous coronary intervention for Non-ST elevation myocardial infarction patients |
| Q47138839 | Contemporary Risk Stratification After Myocardial Infarction in the Community: Performance of Scores and Incremental Value of Soluble Suppression of Tumorigenicity-2. |
| Q38647581 | GDF-15 predicts cardiovascular events in acute chest pain patients. |
| Q93147237 | Growth Differentiation Factor-15 (GDF-15) Is Associated With Mortality in Ischemic Stroke Patients Treated With Acute Revascularization Therapy |
| Q87015006 | Growth Differentiation Factor-15 Is a Novel Biomarker Predicting Acute Exacerbation of Chronic Obstructive Pulmonary Disease |
| Q38041973 | Growth differentiation factor 15 in heart failure: an update |
| Q91274465 | Growth differentiation factor-15 and the risk of cardiovascular diseases and all-cause mortality: A meta-analysis of prospective studies |
| Q94502868 | Growth differentiation factor-15 is a prognostic marker in patients with intermediate coronary artery disease |
| Q91382159 | Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial |
| Q45741016 | Homocysteine enhances the predictive value of the GRACE risk score in patients with ST-elevation myocardial infarction |
| Q51108799 | Improved predictive value of GRACE risk score combined with platelet reactivity for 1-year cardiovascular risk in patients with acute coronary syndrome who underwent coronary stent implantation. |
| Q47597427 | Improved risk stratification of patients with acute coronary syndromes using a combination of hsTnT, NT-proBNP and hsCRP with the GRACE score |
| Q36706382 | Long-term outcomes in high-risk patients with non-ST-segment elevation myocardial infarction |
| Q39822915 | Predictive performance of adding platelet reactivity on top of CRUSADE score for 1-year bleeding risk in patients with acute coronary syndrome |
| Q37441199 | Predictive value of NT-proBNP for 30-day mortality in patients with non-ST-elevation acute coronary syndromes: a comparison with the GRACE and TIMI risk scores |
| Q38009702 | Risk stratification and timing of revascularization: which patients benefit from early versus later revascularization? |
| Q92741974 | Roles of Growth Differentiation Factor 15 in Atherosclerosis and Coronary Artery Disease |
| Q36973936 | Stata Modules for Calculating Novel Predictive Performance Indices for Logistic Models |
| Q39017422 | The Prognostic Value of Heart Type Fatty Acid Binding Protein in Patients with Suspected Acute Coronary Syndrome: A Systematic Review |
| Q35821307 | The ultimate nanoscale mincer: assembly, structure and active sites of the 20S proteasome core. |
| Q87499438 | [Essential cardiac biomarkers in myocardial infarction and heart failure] |
Search more.